Biomarkers in wound drainage fluids of head and neck squamous cell carcinoma patients receiving neck dissection: A pilot study.
Extranodal extension
Head and neck squamous cell carcinoma
Neck dissection
Prognostic biomarkers
Radiotherapy
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
26
02
2020
revised:
17
04
2020
accepted:
21
04
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
22
5
2020
Statut:
epublish
Résumé
In a pilot prospective study, we aimed to test the feasibility and report on the preliminary results on the expression of molecular biomarkers in wound drainage fluids (WDFs) of operated head and neck squamous cell carcinoma (HNSCC) patients. Nineteen patients undergoing primary tumor resection with en-block neck dissection were enrolled. In postoperative days 1-3, the expression of several biomarkers in WDFs was measured using enzyme-linked immunosorbent assay (ELISA) kits and correlated with clinical and histopathologic features. The expression of stromal cell-derived factor 1 (CXCL-12) was significantly increased in WDFs in presence of lymph node metastases, extranodal extension (ENE), and in case of close resection margins. In addition, Osteopontin expression was significantly increased in presence of ENE, whereas transforming growth factor beta (TGF-β) detection was significantly reduced. At multivariate analysis, CXCL-2 levels in both day 1 and 3 post-surgery were the only factor which retained significance in the prediction of close surgical margins (p = 0.028 and 0.025 for day 1 and day 3, respectively). Both CXCL-2 and Ostepontin assays were significantly correlated with ENE (p = 0.018 and 0.035 for day 1; 0.052 and 0.025 for day 3, respectively) whereas TGF- β expression was significant at day 1 only (p = 0.038). Our pilot study showed that WDFs could qualify as a potential source of relevant postoperative information. Further studies are needed to confirm the prognostic impact of CXCL-12, Osteopontin and TGF-β expressed in WDFs on the personalized management of HNSCC.
Identifiants
pubmed: 32435703
doi: 10.1016/j.ctro.2020.04.008
pii: S2405-6308(20)30033-1
pmc: PMC7231969
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60-64Informations de copyright
© 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Clin Chim Acta. 2014 Sep 25;436:35-40
pubmed: 24833243
Surgery. 1989 Sep;106(3):525-32
pubmed: 2772828
Cancer. 2001 Dec 15;92(12):3030-6
pubmed: 11753980
Am J Physiol Cell Physiol. 2007 Mar;292(3):C987-95
pubmed: 16943240
Oncol Lett. 2014 Sep;8(3):1112-1118
pubmed: 25120668
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Breast. 2004 Feb;13(1):49-55
pubmed: 14759716
Otolaryngol Head Neck Surg. 2013 Jul;149(1):105-11
pubmed: 23535708
Head Neck. 2012 Jun;34(6):840-5
pubmed: 22095886
Ann Oncol. 2011 Aug;22(8):1886-93
pubmed: 21343382
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Br J Cancer. 1999 Mar;79(9-10):1392-8
pubmed: 10188881
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
J Surg Res. 2004 Oct;121(2):228-41
pubmed: 15501463
Exp Oncol. 2004 Sep;26(3):179-84
pubmed: 15494684
J Clin Oncol. 2015 Oct 10;33(29):3269-76
pubmed: 26351335
Cancer. 2010 Mar 1;116(5):1291-7
pubmed: 20087960
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):505-11
pubmed: 16257133
J Natl Cancer Inst. 1998 Jun 3;90(11):824-32
pubmed: 9625170
BMC Cancer. 2013 Jan 25;13:33
pubmed: 23351302
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
N Engl J Med. 2000 May 4;342(18):1350-8
pubmed: 10793168